Dr. William F. Rencher Ph.D. Net Worth

Dr. William F. Rencher Ph.D. biography

Dr. William F. Rencher Ph.D. is the Head of CMC & Regulatory at Centrexion Therapeutics.

What is the salary of Dr D?

As the Head of CMC & Regulatory of Centrexion Therapeutics, the total compensation of Dr D at Centrexion Therapeutics is $246,470. There are 2 executives at Centrexion Therapeutics getting paid more, with Jennifer Minai-Azary having the highest compensation of $404,331.

How old is Dr D?

Dr D is 62, he's been the Head of CMC & Regulatory of Centrexion Therapeutics since . There are 1 older and 4 younger executives at Centrexion Therapeutics. The oldest executive at Centrexion Therapeutics Corporation is Dr. Evan G. Dick, 69, who is the Sr. VP of R&D.

What's Dr D's mailing address?

William's mailing address filed with the SEC is 2001 MARKET STREET, SUITE 3915, UNIT#15, PHILADELPHIA, PA, 19103.

Insiders trading at Centrexion Therapeutics

Over the last 3 years, insiders at Centrexion Therapeutics have traded over $0 worth of Centrexion Therapeutics stock and bought 152,118 units worth $245,330 . The most active insiders traders include Richard J Berman, Martin A. Lehr, and Linda West. On average, Centrexion Therapeutics executives and independent directors trade stock every 32 days with the average trade being worth of $21,702. The most recent stock trade was executed by Martin A. Lehr on 21 February 2023, trading 5,823 units of CNTX stock currently worth $4,891.

What does Centrexion Therapeutics do?

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Centrexion Therapeutics executives and stock owners

Centrexion Therapeutics executives and other stock owners filed with the SEC include:

• Jennifer Minai-Azary,
  CFO & Treasurer
• Martin A. Lehr,
  Co-Founder, CEO & Director
• Dr. William F. Rencher Ph.D.,
  Head of CMC & Regulatory
• Dr. Tarek Sahmoud M.D., Ph.D.,
  Chief Medical Officer
• Elizabeth Nemchik CPA,
  Controller
• Christopher Beck M.B.A.,
  Sr. VP of Operations
• Eileen Kittrick CPA,
  Controller
• Dr. Evan G. Dick,
  Sr. VP of R&D
• Alex C. Levit Esq.,
  Chief Legal Officer & Corp. Sec.
• Dr. Felix Kim Ph.D.,
  Co-founder & Chair of Scientific Advisory Board
• Luke Nathaniel Walker,
  Director
• Karen L. Smith,
  Director
• Jennifer Lynn Minai Azary,
  Chief Financial Officer
• William F. Rencher,
  
• Evan G. Dick,
  
• Martin A. Lehr,
  Chief Executive Officer
• Alex C. Levit,
  Chief Legal Officer, Corp. Sec
• Philip W. Kantoff,
  Director
• Jennifer Evans Stacey,
  Director
• Linda West,
  Director
• Richard J Berman,
  Director
• Tarek Sahmoud,
  Chief Medical Officer
• Ullmann Claudio Dansky,
  Chief Medical Officer